Shopping Cart 0
Cart Subtotal
USD 0

Somatostatin Receptor Type 4 (SSTR4)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Somatostatin Receptor Type 4 (SSTR4)-Pipeline Review, H2 2017

Summary

Somatostatin Receptor Type 4 (SSTR4)-Somatostatin receptor type 4 is a protein encoded by the SSTR4 gene. The activity of receptor is mediated by G proteins which inhibits adenylyl cyclase. It mediates antiproliferative action of somatostatin in tumor cells. It is functionally coupled to inhibition of adenylate cyclase and activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade.

Somatostatin Receptor Type 4 (SSTR4) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I and Discovery stages are 1, 1 and 3 respectively. Report covers products from therapy areas Central Nervous System, Hormonal Disorders, Metabolic Disorders and Oncology which include indications Chronic Pain, Neuropathic Pain, Acromegaly, Diabetic Retinopathy, Gastrointestinal Tumor, Inflammatory Pain, Neuroendocrine Tumors, Pancreatic Tumor and Pituitary ACTH Hypersecretion (Cushing Disease).

The latest report Somatostatin Receptor Type 4 (SSTR4)-Pipeline Review, H2 2017, outlays comprehensive information on the Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 4 (SSTR4)

The report reviews Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics and enlists all their major and minor projects

The report assesses Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 4 (SSTR4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it'smost promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 4 (SSTR4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Somatostatin Receptor Type 4 (SSTR4)-Overview

Somatostatin Receptor Type 4 (SSTR4)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Somatostatin Receptor Type 4 (SSTR4)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Somatostatin Receptor Type 4 (SSTR4)-Companies Involved in Therapeutics Development

Centrexion Therapeutics Corp

Crinetics Pharmaceuticals Inc

Strongbridge Biopharma plc

Somatostatin Receptor Type 4 (SSTR4)-Drug Profiles

CNTX-0290-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize SSTR4 for Chronic Pain and Neuropathic Pain-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Somatostatin Receptor Type 4 (SSTR4)-Dormant Products

Somatostatin Receptor Type 4 (SSTR4)-Product Development Milestones

Featured News & Press Releases

Jul 18, 2017: Centrexion Provides Pipeline Updates, Plans for Phase 2 Study of Pain Drug Candidate CNTX-0290

May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology

Apr 27, 2015: Crinetics Pharmaceuticals Awarded NIH Fast-Track Grant to Develop Somatostatin Receptor Agonist Drugs for Chronic Pain

Apr 22, 2014: Aspireo Reports Data in Further Phase Ib Study

Sep 25, 2013: FDA Grants Orphan Drug Designation for Aspireo'sSomatoprim

Jun 18, 2013: Aspireo Reports Start of Further Phase I Study in Healthy Volunteers

Apr 03, 2013: Aspireo Pharma Reports Somatoprim Phase IIa Proof Of Concept Results In Acromegaly

Jan 07, 2013: Aspireo Pharma Reports Phase Ib Interim Data For Somatoprim

Nov 26, 2012: Aspireo Pharma Announces EMA's Committee For Orphan Medicinal Products Recommends Orphan Medicinal Product Designation For Somatoprim

Nov 06, 2012: Aspireo Pharma Starts Somatoprim Phase IIa Study In Acromegaly Patients

Sep 28, 2012: Evotec And Aspireo Pharma Enter Into Strategic Advisory Agreement For Somatoprim

Jun 26, 2012: Somatoprim is a potent agonist of Somatostatin Receptors 2 and

Apr 05, 2012: Aspireo Starts Phase I Multi Ascending Dose Study with Somatoprim

Feb 26, 2009: DeveloGen Reports Positive Phase I Clinical Trial Results for DG

Oct 08, 2008: DeveloGen Announces Completion Of A Phase I Clinical Trial Of DG3173, A Novel Somatostatin Analogue For The Treatment Of Acromegaly

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Centrexion Therapeutics Corp, H2 2017

Pipeline by Crinetics Pharmaceuticals Inc, H2 2017

Pipeline by Strongbridge Biopharma plc, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Dormant Products, H2 2017 (Contd..2), H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Centrexion Therapeutics Corp

Crinetics Pharmaceuticals Inc

Strongbridge Biopharma plc